Intellia Therapeutics Investor Presentation
Intellia Therapeutics hosted a webcast and filed a formal investor presentation titled 'Readying Lonvo-z for Patients with HAE.' The presentation focused on the commercial potential and clinical data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema.